Granules India shares rise after USFDA EIR in 2026

Stock reaction: a regulatory update lifts sentiment

Shares of Granules India Ltd gained as much as 2% on Wednesday, June 3, after the company disclosed an update from the US Food and Drug Administration (USFDA) for its US operations. In the session, the stock was reported up 1.69% at Rs 789.95 after the disclosure. In a separate market update, Granules India was cited trading at Rs 621.45 on the BSE, up 1.21% from the previous close of Rs 614.00. The company’s filings and subsequent reports focused on inspection outcomes for its US facilities, a key sensitivity for Indian pharma exporters.

USFDA EIR for Chantilly: VAI classification and what it signals

Granules India said its wholly owned subsidiary, Granules Pharmaceuticals Inc. (GPI), received an Establishment Inspection Report (EIR) from the USFDA for its facility in Chantilly, Virginia. The USFDA classified the inspection as Voluntary Action Indicated (VAI). This classification indicates that the regulator made certain observations, but they do not warrant regulatory or enforcement action. Granules India described the receipt of the EIR with a VAI classification as the successful closure of the inspection.

Inspection details: four Form 483 observations, no enforcement action

The USFDA inspection at the Chantilly facility was conducted between March 30 and April 3, 2026. During this inspection, the regulator issued four observations in Form 483. Another report on the same inspection described the exercise as a routine current Good Manufacturing Practices (cGMP) audit, and said the observations were related to procedural matters. It also stated that no data integrity related observations were reported during the inspection. The inspection was described as the second USFDA inspection at the Chantilly facility in the last one year.

Why the Chantilly facility matters to Granules India

In its exchange filing, Granules India said the Chantilly facility plays a key role in its global manufacturing and supply network. The company linked the update to its focus on quality systems, regulatory compliance and patient safety. For investors, the key takeaway in the disclosure was that the inspection has been closed with a VAI status, rather than escalating into a more serious regulatory outcome.

Another US facility update: Manassas packaging site gets NAI

Separate from the Chantilly update, Granules India also disclosed an inspection outcome for its US step-down subsidiary, Granules Consumer Health LLC. The company said the packaging site in Manassas, Virginia, received a No Action Indicated (NAI) Establishment Inspection Report from the USFDA. The FDA inspection at this packaging site took place from Dec 1 to 3, 2025. The report was issued on March 5, 2026, and recorded zero observations.

Second clean inspection at Manassas after March 2023

Granules India stated that the March 5, 2026 EIR marked the second successful inspection for the Manassas facility after a similar result in March 2023. In another update around the same facility, the company said it had successfully completed a GMP inspection with zero observations, and described it as the second FDA inspection after the March 2023 audit that resulted in an NAI classification. On that day, the stock rose as much as 1% to Rs 574.40 on the NSE, and was quoted up 0.48% at Rs 571 at 12:44 pm.

Product pipeline: tentative approval and 180-day exclusivity

Beyond inspections, Granules India also reported a USFDA tentative approval for an Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. The tentative approval covers generic amphetamine extended-release tablets, equivalent to DYANAVEL XR, for the treatment of attention deficit hyperactivity disorder (ADHD). The company said the ANDA has been determined eligible for 180-day exclusivity. The approved strengths were reported as 5 mg, 10 mg, 15 mg, and 20 mg.

In another reference to ADHD products, Granules Pharmaceuticals earlier received tentative approval on December 22, 2025 for amphetamine extended-release orally disintegrating tablets in multiple strengths, the generic equivalent of ADZENYS XR-ODT. In a market note tied to the exclusivity opportunity, Granules India highlighted an estimated US market size of around $11 million for the product, with only one other approved generic and one authorized generic available. The same note cited a total addressable market share estimated at $172 million.

India facility inspection: Hyderabad site received five observations

Granules India also disclosed an inspection outcome for its Hyderabad manufacturing facility through Granules Life Sciences Private Ltd. The company said the USFDA conducted a Good Manufacturing Practices and prior approval inspection from December 15 to December 19, 2025. The inspection resulted in five observations, described as related primarily to procedural requirements. Granules India said none of these observations were associated with data integrity or product safety concerns. The company said it would submit its response to the USFDA within the stipulated timeframe.

Financial snapshot: Q4 FY26 growth and Q2 FY26 decline

The regulatory updates came alongside recent financial disclosures. Granules India reported consolidated net profit climbed 32.58% to Rs 201.56 crore on a 22.81% increase in revenue from operations to Rs 1,470.60 crore in Q4 FY26 over Q4 FY25. In a separate quarterly comparison, the company reported consolidated net profit declined 16.3% to Rs 112.64 crore, while net sales increased 3.4% to Rs 1,208.79 crore in Q2 FY26 compared with Q2 FY25. One market report also cited the company’s market capitalization at Rs 15,044 crore at the time of a stock move linked to the ADHD product update.

Key facts at a glance

Why this matters for investors tracking US-facing pharma names

For Indian pharma companies, USFDA inspection outcomes can influence supply continuity and customer confidence, so EIR classifications often drive near-term trading moves. In Granules India’s case, the Chantilly EIR carried a VAI classification, which the company linked to inspection closure without enforcement action. The Manassas packaging site outcome was stronger, with an NAI report and zero observations. Alongside facility compliance updates, the company’s US pipeline development includes tentative approvals and a stated 180-day exclusivity eligibility for an ADHD product, which can be commercially relevant once launch conditions are met.

Conclusion

Granules India’s recent disclosures span multiple USFDA touchpoints, including a VAI-classified EIR for its Chantilly facility, an NAI EIR with zero observations for its Manassas packaging site, and tentative approvals in its US generics pipeline. The company has also outlined procedural observations at its Hyderabad unit and cited plans to respond within timelines. Investors will continue to watch for follow-up actions tied to Form 483 responses, future EIR outcomes, and any updates on product launch timing for the ADHD portfolio.